Clinical trial · Observational
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma
NCT06436040CI-TRIAL-00077607unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Squamous Cell Carcinoma | Lung Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Neoadjuvant Chemoimmunotherapy | — | UNRESOLVED | — |
| Tumor Microenvironment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pathological response assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- MPR(major pathological response)
- description
- defned as having no more than 10% residual viable tumor cells by routine hematoxylin and eosin (H\&E) staining after therapy
- interventionNames
- Other: Pathological response assessment
- label
- non-MPR
- description
- defned as having more than 10% residual viable tumor cells by routine hematoxylin and eosin (H\&E) staining after therapy
- interventionNames
- Other: Pathological response assessment
Primary outcomes (1)
- measure
- Pathological response assessment
- timeFrame
- through study completion, an average of 2 year
- description
- MPR: Resected tumors with ≤10% viable tumor cells were considered to have a MPR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. aged 40 to 80 years; 2. had histologically confirmed LUSC with operable locally advanced stage 3. no prior anti-tumor therapy; received neoadjuvant immunotherapy consisting of three cycles of anti-PD-1 ICB plus nab-paclitaxel and carboplatin 4. pre-treatment tissues Exclusion Criteria: 1. the presence of central nervous system metastases 2. the presence of immunodeficiency disease; previous therapies with immunosuppressants within 14 days prior to the initiation of study treatment; 3. uncontrolled hypertension 4. history of or having pulmonary fibrosis or interstitial lung disease
References
Publications (0)
Data not yet available
No reference posted for this study.